ASCO24 Abstracts of High Interest by ECOG-ACRIN
During the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting ECOG-ACRIN presented the following abstracts on different topics from oncology.
- ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer. Presented by Tarah J. Ballinger.
A prospective trial that enrolled only Black women. Seeking to not just describe disparities but to begin to understand and address them to improve equity in breast cancer care. One of the first trials to focus specifically on enrolling a minority population to assess drug-induced toxicity (rather than drug efficacy) where there are known disparate outcomes.
- A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174). Presented by Jennifer R. Eads.
This type of cancer has a high mortality rate despite curative intent therapy. While immune checkpoint inhibition in combination with chemotherapy in the metastatic setting and as adjuvant monotherapy both confer survival benefits, this trial sought to clarify its role in combination with neoadjuvant chemoradiation.
- Long-term follow up of E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group. Presented by Barbara A. Burtness.
Follow-up on a practice-changing approach using less radiation.
- A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186. Presented by Efrat E. Dotan.
The first randomized trial for elderly patients with metastatic disease who are not candidates for standard therapy – A new approach in geriatric oncology. This trial will lead the way in the conduct of elderly-specific clinical trials regardless of cancer type.
- Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153). Presented by Christos P. Kyriakopoulos.
A follow-on to the landmark E3805 (CHAARTED) trial that showed a significant survival benefit from early treatment with chemohormonal therapy (ADT+doxetaxel). This trial explored whether additional treatment with chemohormonal therapy will improve outcomes.
- Prognostic validation of a digital pathology-based multi-modal artificial intelligence (MMAI) biomarker in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the CHAARTED trial (ECOG-ACRIN EA3805). Presented by Mark C. Markowski.
A promising artificial intelligence (AI) approach. The ArteraAI prostate test is the first of its kind to risk stratify patients with localized prostate cancer. This exploratory analysis aimed to validate the test for metastatic disease – It used a repository of digital histopathology images and clinical data from a previous trial.
More content from ASCO24 on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023